Vincristine induced cranial polyneuropathy

Indian Journal of Pediatrics

Volumn 73, Issue 6, 2006, Pages 531-533

  Ali, Bay ^a   Yilmaz, Cahide ^a   Yilmaz, Nebi ^a   Oner, Ahmet Faik ^a  

^a YUZUNCU YIL UNIVERSITY   (Turkey)

Author keywords

Ptosis; Treatment; Vincristine

Indexed keywords

ASPARAGINASE; DAUNORUBICIN; METHYLPREDNISOLONE; PREDNISOLONE; PYRIDOSTIGMINE; PYRIDOXINE; VINCRISTINE; ANTINEOPLASTIC AGENT; CHOLINESTERASE INHIBITOR; VITAMIN B COMPLEX;

ACUTE LYMPHOBLASTIC LEUKEMIA; ARTICLE; CASE REPORT; CHEMOTHERAPY; CRANIAL NEUROPATHY; FEMALE; HUMAN; NEUROLOGIC EXAMINATION; OPHTHALMOPLEGIA; PRESCHOOL CHILD; PTOSIS; ACUTE LYMPHOCYTIC LEUKEMIA; CHEMICALLY INDUCED DISORDER; POLYNEUROPATHY;

ANTINEOPLASTIC AGENTS, PHYTOGENIC; BLEPHAROPTOSIS; CHILD, PRESCHOOL; CHOLINESTERASE INHIBITORS; CRANIAL NERVE DISEASES; FEMALE; HUMANS; LEUKEMIA, LYMPHOCYTIC, ACUTE; OPHTHALMOPLEGIA; POLYNEUROPATHIES; PYRIDOSTIGMINE BROMIDE; PYRIDOXINE; VINCRISTINE; VITAMIN B COMPLEX;

EID: 33746749543     PISSN: 00195456     EISSN: None     Source Type: Journal    
DOI: 10.1007/BF02759902     Document Type: Article

References (10)

1. Quasthoff S, Hartung HP. Chemotherapy-induced peripheral neuropathy. J Neurol 2002; 249: 9-17.
2. Chauvenet AR, Shashi V, Selsky C, Morgan E, Kurtzberg J, Bell B Vincristine-induced neuropathy as the initial presentation of charcot-marie-tooth disease in acute lymphoblastic leukemia: a Pediatric Oncology Group study. J Pediatr Hematol Oncol 2003; 25 : 316-320.
3. Moudgil SS, Riggs JE. Fulminant peripheral neuropathy with severe quadriparesis associated with vincristine therapy. Ann Pharmacother 2000; 34 : 1136-1138.
4. Legha SS. Vincristine neurotoxicity. Pathophysiology and management. Med Toxicol 1986; 1 : 421-427.
5. Yetgin S, Tuncer MA, Cetin M et al. Benefit of high-dose methylprednisolone in comparison with conventional-dose prednisolone during remission induction therapy in childhood acute lymphoblastic leukemia for long-term follow-up. Leukemia 2003; 17 : 328-333.
6. Chan JD. Pharmacokinetic drug interactions of vinca alkaloids: summary of case reports. Pharmacotherapy 1998; 18 : 1304-1307.
7. Neumann Y, Toren A, Rechavi G et al. Vincristine treatment triggering the expression of asymptomatic Charcot-Marie-Tooth disease. Med Pediatr Oncol 1996; 26 : 280-283.
8. Jackson DV, Jr., Pope EK, McMahan RA et al. Clinical trial of pyridoxine to reduce vincristine neurotoxicity. J Neurooncol 1986; 4 : 37-41.
9. Battle WM, Snape WJ, Jr., Alavi A et al. Colonic dysfunction in Diabetes mellitus. Gastroenterology 1980; 79 : 1217-1221.
10. Muller L, Kramm CM, Tenenbaum T, Wessalowski R, Gobel U. Treatment of vincristine-induced bilateral ptosis with pyridoxine and pyridostigmine. Pediatr Blood Cancer 2004; 42 : 287-288.